Philogen (was founded in 1996 with the mission to develop new biopharmaceuticals for the treatment of angiogenesis-related disorders, such as cancer and rheumatoid arthritis. The company has been a pioneer in the isolation, engineering and clinical development of lead products capable of targeting angiogenesis in vivo and has been the first in the world to demonstrate that human monoclonal antibodies, specific for a marker of angiogenesis, can efficiently and selectively target the tumour neo- vasculature both in animal models and in cancer patients.

Philogen owns two industrial buildings of > 5,000 in Siena, Italy, including a GMP production facility of approx. 1.800 mq authorized for the production of clinical-grade biopharmaceuticals. At present, the company has four promising anti-cancer antibody derivatives and an antibody-derivative for the treatment of rheumatoid arthritis in >10 international clinical studies. Philogen generates revenues from a diversified range of activities, has signed agreements with major pharmaceutical companies and owns a diversified portfolio of international patents, and is profitable each year since 1999. Philogen has participated in numerous FP6 and FP7 EU Projects, including the FP6 Projects Immuno- PDT and STROMA.